Jazz Pharmaceuticals plc (JAZZ)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 146.49 |
| Open | 146.83 |
| Bid | 101.00 x 800 |
| Ask | 160.00 x 800 |
| Day's range | 146.60 - 149.17 |
| 52-week range | 117.64 - 189.00 |
| Volume | |
| Avg. volume | 591,703 |
| Market cap | 9.17B |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
JAZZ Q1 Earnings Miss, Sales Robust, 2022 Guidance Raised
JAZZ's product revenues grow in the first quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals. It raises guidance on strong results.
- Zacks
Jazz Pharmaceuticals (JAZZ) Lags Q1 Earnings and Revenue Estimates
Jazz (JAZZ) delivered earnings and revenue surprises of -0.53% and 4.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
© 2022 Yahoo. All rights reserved.
